Jaye Thompson Acquires 800 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) VP Jaye Thompson bought 800 shares of Greenwich LifeSciences stock in a transaction on Monday, August 12th. The shares were acquired at an average price of $13.85 per share, for a total transaction of $11,080.00. Following the completion of the acquisition, the vice president now owns 263,148 shares in the company, valued at $3,644,599.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Jaye Thompson also recently made the following trade(s):

• On Friday, August 2nd, Jaye Thompson acquired 1,000 shares of Greenwich LifeSciences stock. The shares were bought at an average cost of $15.15 per share, for a total transaction of $15,150.00.
• On Thursday, July 18th, Jaye Thompson bought 1,000 shares of Greenwich LifeSciences stock. The stock was bought at an average price of $16.00 per share, with a total value of $16,000.00.

Greenwich LifeSciences Stock Up 0.1 %

Shares of NASDAQ:GLSI opened at $14.46 on Wednesday. Greenwich LifeSciences, Inc. has a fifty-two week low of $7.58 and a fifty-two week high of $21.44. The firm’s 50 day moving average price is $14.62 and its 200 day moving average price is $15.12. The stock has a market cap of $186.24 million, a price-to-earnings ratio of -20.08 and a beta of 1.61.

Greenwich LifeSciences (NASDAQ:GLSI) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.20) EPS for the quarter, meeting analysts’ consensus estimates of ($0.20). On average, equities analysts anticipate that Greenwich LifeSciences, Inc. will post -0.81 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright increased their price target on Greenwich LifeSciences from $36.00 to $38.00 and gave the company a “buy” rating in a research report on Friday, August 23rd.

Hedge Funds Weigh In On Greenwich LifeSciences

Several large investors have recently bought and sold shares of the business. Rhumbline Advisers purchased a new stake in Greenwich LifeSciences during the 2nd quarter worth about $117,000. Bank of New York Mellon Corp acquired a new stake in shares of Greenwich LifeSciences during the 2nd quarter worth about $264,000. Finally, Vanguard Group Inc. lifted its stake in Greenwich LifeSciences by 0.6% during the first quarter. Vanguard Group Inc. now owns 223,102 shares of the company’s stock worth $4,449,000 after purchasing an additional 1,420 shares during the last quarter. Hedge funds and other institutional investors own 4.16% of the company’s stock.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.